Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Endometrial Cancer Clinical Trials

A listing of Endometrial Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (17) clinical trials

Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer

Stage 1 Study Visits: The Levonorgestrel IUD: This study will have 2 stages. If you are found to be eligible to take part in this study, in Stage 1, you will receive the levonorgestrel IUD. The levonorgestrel IUD is a T-shaped birth control device that is made of flexible plastic. ...


Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to either the Safety Lead-in or the Phase 2 portion. The study group you are in will depend on when you join the study. In the Safety Lead-in, each study cycle ...


Phase 2 Study of MLN0128 Combination of MLN0128 With MLN1117 Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer

The drugs being evaluated in this study are MLN0128 and MLN1117. MLN0128 is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. This study will evaluate the efficacy and safety of each drug or drug combination. ...


Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

This is an open label pilot study to evaluate the safety, tolerability, and efficacy of the combination of Vigil autologous tumor cell immunotherapy and durvalumab PD-L1 inhibitor in patients with locally advanced or metastatic women's cancers, inclusive, but not limited to breast, ovarian, cervical, uterine, fallopian, primary peritoneal, and endometrial ...


Study of Ribociclib (LEE011) Everolimus and Letrozole in Patients With Advanced or Recurrent Endometrial Carcinoma

Study Drug Administration: Each study cycle is 28 days. Participant will take everolimus, letrozole and ribociclib by mouth and should be swallowed whole without opening, chewing, or crushing 1 time every day at the same time. Participant will take the dose in the morning with a full cup of water ...


An Endometrial Cancer Study of Sodium Cridanimod in Conjunction With Progestin Therapy

Treatment Period 1 (Progestin Monotherapy): During Treatment Period 1, all subjects determined to be PrR positive will receive progestin monotherapy, megestrol acetate, for up to 14 weeks. Subjects will have an MRI or CT scan after 12 weeks of progestin monotherapy, with response to treatment being assessed according to RECIST ...


Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

ONC201 is a small molecule which selectively targets the G protein-coupled receptor DRD2. Downstream of target engagement, ONC201 activates the integrated stress response (ISR) in tumor cell leading to inactivation of Akt and extracellular signal-regulated kinase (ERK) signaling as well as induction of the TRAIL pathway. ONC201 also inhibits dopamine ...


Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Primary Objectives: To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of pembrolizumab with objective tumor response in patients with persistent, recurrent or metastatic endometrial cancer harboring an ultra-mutated or hyper-mutated (MMR gene-defective) phenotype identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP). To ...


Study of Avelumab in Patients With MSS MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more ...


Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer

OBJECTIVES: Primary - Measure quality of life (QLQ-C30) at week 18 in patients with metastatic gynecological cancer receiving systematic nutritional supplements during first-line chemotherapy. Secondary - Study the maintenance or improvement of intake and nutritional status. - Study the quality of life during chemotherapy. - Evaluate tolerance and compliance to ...